The Efficacy and Safety of Rituximab in Patients with Idiopathic Inflammatory Myopathy-Associated Interstitial Lung Disease: Case Series.

J Clin Med · 2023 · PMC10219281 · PMID 37240516

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

marginal significanceno p-value reported

However, in the present study, disease progression in FVC decreased with marginal significance after rituximab treatment, while disease progression in DLco did not change after rituximab treatment.

also in 5,069 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.